Epoch Investment Partners Inc. Sells 1,010 Shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Epoch Investment Partners Inc. reduced its stake in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 8.5% during the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 10,874 shares of the medical equipment provider’s stock after selling 1,010 shares during the period. Epoch Investment Partners Inc.’s holdings in Zimmer Biomet were worth $1,180,000 at the end of the most recent quarter.

A number of other institutional investors have also made changes to their positions in ZBH. Chicago Partners Investment Group LLC boosted its holdings in shares of Zimmer Biomet by 3.3% in the 4th quarter. Chicago Partners Investment Group LLC now owns 2,894 shares of the medical equipment provider’s stock valued at $349,000 after buying an additional 92 shares during the last quarter. North Star Investment Management Corp. lifted its stake in Zimmer Biomet by 16.6% in the first quarter. North Star Investment Management Corp. now owns 669 shares of the medical equipment provider’s stock valued at $88,000 after acquiring an additional 95 shares during the last quarter. Ballentine Partners LLC grew its position in shares of Zimmer Biomet by 2.6% in the 1st quarter. Ballentine Partners LLC now owns 3,957 shares of the medical equipment provider’s stock valued at $522,000 after acquiring an additional 100 shares during the period. First Bancorp Inc ME increased its stake in shares of Zimmer Biomet by 5.3% during the 1st quarter. First Bancorp Inc ME now owns 1,970 shares of the medical equipment provider’s stock worth $260,000 after purchasing an additional 100 shares during the last quarter. Finally, Romano Brothers AND Company raised its holdings in shares of Zimmer Biomet by 1.1% in the 1st quarter. Romano Brothers AND Company now owns 9,514 shares of the medical equipment provider’s stock valued at $1,256,000 after purchasing an additional 100 shares during the period. 88.89% of the stock is owned by institutional investors and hedge funds.

Zimmer Biomet Price Performance

Shares of NYSE:ZBH opened at $107.57 on Tuesday. The company has a current ratio of 1.29, a quick ratio of 0.63 and a debt-to-equity ratio of 0.31. The stock has a market capitalization of $22.13 billion, a PE ratio of 23.28, a PEG ratio of 1.96 and a beta of 1.02. The firm has a 50 day moving average of $109.86 and a 200-day moving average of $115.25. Zimmer Biomet Holdings, Inc. has a 12 month low of $102.00 and a 12 month high of $133.90.

Zimmer Biomet (NYSE:ZBH) last issued its quarterly earnings results on Wednesday, August 7th. The medical equipment provider reported $2.01 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.99 by $0.02. The company had revenue of $1.94 billion for the quarter, compared to analyst estimates of $1.94 billion. Zimmer Biomet had a return on equity of 12.86% and a net margin of 13.25%. The company’s revenue for the quarter was up 3.9% compared to the same quarter last year. During the same quarter last year, the company posted $1.82 EPS. On average, equities research analysts predict that Zimmer Biomet Holdings, Inc. will post 8.02 EPS for the current fiscal year.

Zimmer Biomet Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Thursday, October 31st. Investors of record on Monday, September 30th will be issued a dividend of $0.24 per share. This represents a $0.96 annualized dividend and a dividend yield of 0.89%. The ex-dividend date of this dividend is Monday, September 30th. Zimmer Biomet’s dividend payout ratio (DPR) is presently 20.78%.

Analyst Upgrades and Downgrades

A number of equities analysts have weighed in on the company. Canaccord Genuity Group lowered their price target on Zimmer Biomet from $120.00 to $115.00 and set a “hold” rating on the stock in a research report on Tuesday, September 10th. JPMorgan Chase & Co. decreased their target price on Zimmer Biomet from $125.00 to $120.00 and set a “neutral” rating on the stock in a report on Monday, September 16th. TD Cowen cut their price target on Zimmer Biomet from $143.00 to $119.00 and set a “hold” rating for the company in a report on Friday, September 6th. Evercore ISI reaffirmed an “in-line” rating and set a $113.00 price objective on shares of Zimmer Biomet in a research report on Thursday, September 5th. Finally, Citigroup dropped their price objective on shares of Zimmer Biomet from $134.00 to $120.00 and set a “neutral” rating on the stock in a research report on Wednesday, July 10th. Two research analysts have rated the stock with a sell rating, twelve have given a hold rating and seven have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $125.17.

Zimmer Biomet Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.